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aBstraCt
introduCtion. The aim of our study is to describe the anatomical and functional results of pars plana vitrectomy 
(PPV) among diabetic patients treated due to tractional retinal detachment (TRD) or non-clearing vitreous haemor-
rhage (VH).
MateriaLs and Methods. A retrospective analysis was made of clinical data of 45 eyes treated with 23G PPV 
for TRD (17 eyes) or VH (28 eyes). Preoperative and final visual outcomes and postoperative complications were 
recorded. The mean follow-up period was 12 months.
resuLts. The postoperative visual acuity (VA) improved significantly in 60% of eyes, but remained unchanged or 
was worse in 40%. Improvement of VA was more pronounced in the VH group. PPV was performed with silicone 
oil tamponade in 66.5%, air tamponade in 29%, and gas tamponade in 4.5%. Postoperative complications included: 
retinal re-detachment (seven eyes), secondary glaucoma (nine eyes), and recurrent VH (two eyes).
ConCLusions. PPV is an effective treatment method of complications of severe proliferative diabetic retinopathy 
inter alia the TRD and VH. Because surgical management of TRD and VH is demanding, anatomical and functional 
results are limited by complications.
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introduCtion
Diabetes mellitus is a common chronic meta-
bolic disease wherein the frequency of morbidi-
ty increases. The common complications of severe 
proliferative diabetic retinopathy (PDR) include 
vitreous haemorrhage (VH), as well as tractional 
retinal detachment (TRD). Both are indications for 
vitreoretinal surgery [1].
The concept of pars plana vitrectomy (PPV) 
began in 1971 by Machemer [2] and was first in-
troduced with 20 G instrumentation in 1972 by 
O’Malley and Heintz [3]. Since then, the surgical 
instrumentation has been permanently improved. 
In 2005, Eckardt developed the 23 G instrumen-
tation [4]. Vitrectomy instruments are now avail-
able also in 25 and 27 gauge, which are better for 
navigation. The cutting speeds are increasing (up to 
7500-8000 cuts per minute), which allows extreme-
ly precise cutting. The combination of high cutting 
speeds and small gauge instruments allows success-
ful surgery in severe complications of PDR. PPV 
gives the possibility of removal of the fibrovascular 
tissue and blood from the vitreous cavity [5, 6]. 
However, there is a risk of surgically induced com-
plications, such as bleeding and VH, iatrogenic ret-
inal breaks, recurrent RD, and glaucoma.
This article describes the evaluation of the results 
and complication rates among diabetic patients 
treated with PPV due to TRD or VH.
MateriaLs and Methods
A retrospective analysis was performed on 45 eyes 
of 41 patients with PDR, who underwent surgery 
for the complications of PDR, TRD, or VH, in the 
Department of General Ophthalmology of Medical 
University of Lublin in Poland. The surgeries were con-
ducted between January 2012 and December 2015. 
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Figure 1. Tractional retinal detachment (a); vitreous haemorrhage in ultrasonography (B) — B scan
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All the patients were informed about the possible 
complications and everyone signed the agreement. 
The inclusion criteria were as follows: 
•	 presence of TRD or 
•	 non-clearing VH for more than three months.
Collected medical data were as follows: the type 
of diabetes, the duration of diabetes, the rubeosis 
iridis or the cataract presence, type of the tampon-
ade used during PPV, preoperative and final best 
corrected visual acuity (BCVA), and postoperative 
complications, e.g.: secondary glaucoma, recurrent 
TRD, or recurrent VH. The main result measures 
were final visual outcomes and surgical complica-
tions. Each patient underwent a full ophthalmic ex-
amination, including BCVA testing with the Snel-
len method, slit lamp examination, measurement 
of intraocular pressure, and ultrasonography ty - 
pe B (Fig. 1). Snellen visual acuity records were con-
verted to the logarithm of the minimum angle of 
resolution (LogMAR) value for statistical analysis. 
The schedule of postoperative examinations was 
as follows: first day, 2 weeks, 6 weeks, and 4, 6, 9, 
12, 15, and 18 months after surgery. 
PPV is gaining popularity in the treatment of sur-
gical vitreoretinal conditions because it may give fast-
er recovery, but it requires a conjunctival peritomy. 
Statistical analyses were performed using Graph-
Pad Prism 5 software.
surgiCaL teChniQue
Standard 23 G PPV was performed in local or 
general anaesthesia using the Constellation system 
(Alcon, Fort Worth, Texas, US). Complete PPV 
with assistance of triamcinolone and scleral indent-
ing was performed. In order to avoid retinal dam-
age, posterior vitreous detachment was not per-
formed on the posterior pole. ILM peeling after 
indocyanine green (ICG) was performed if tractions 
were present in the posterior pole. The tractional 
membranes were removed bimanually using deline-
ation and segmentation techniques. Panretinal laser 
coagulation was performed intraoperatively in each 
case. At the end of surgery, air, gas, or silicone 
oil was used as a tamponade. Sclerotomies were 
checked for leakage, and if needed, a Vicryl suture 
was applied (Fig. 2).
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Figure 2. Intraoperative photographs: a. Shaving the vitreous base during the vitrectomy; B. Removing fibrovascular tissue in the posterior 
pole; C. Photocoagulation of the peripheral retina
Figure 3. Postoperative (post-OP) versus preoperative (pre-OP) 
visual acuity (LogMAR)
resuLts
The study included 45 eyes of 41 patients with 
complications for PDR: TRD (17 eyes, i.e. 38%) 
or VH (i.e. 28 eyes, i.e. 62%). The cohort included 
23 men (57%) and 18 women (43%) aged from 
25 to 84 years. Eight (20%) patients were diag-
nosed with type I diabetes and 33 (80%) patients 
with type 2 diabetes. The mean duration of diabetes 
was 14.5 years (range 1–34 years). Neovascularisa-
tion of the iris was recognised in eight eyes (18%). 
Laser endophotocoagulation was performed in all 
eyes before PPV. Preoperative BCVA was between 
20/40 and 20/400 in 13 eyes (29%), counting fin-
gers in 10 eyes (22%), and hand movements or light 
perception in 22 eyes (49%). The mean follow-up 
period was 12 months. In 11 patients (i.e. 26%) an 
intraocular lens was implanted during PPV (one 
patient had aphakia), and 30 patients (73%) had 
pseudophakia before PPV. In 12 cases (27%) ILM 
peeling was performed after dying with ICG dur-
ing PPV. The primary PPV was performed with 
gas tamponade in two eyes (i.e. 4.5%), silicone oil 
tamponade in 30 eyes (i.e. 66.5%), and air tam-
ponade in 13 eyes (i.e. 29%). The postoperative 
BCVA improved significantly in 27 eyes (60%) 
and remained unchanged or was worse in 18 eyes 
(40%); however, visual acuity was hand movements 
or light perception in these eyes. The preopera-
tive logMAR BCVA changed from 1.64 ± 0.07 to 
1.41 ± 0.08 postoperatively (Fig. 3). The preopera-
tive logMAR BCVA changed from 1. 71 ± 0.12 to 
1.69 ± 0.14 postoperatively among patients with 
I type diabetes. The preoperative logMAR BCVA 
changed from 1.80 ± 0.09 to 1.40 ± 0.10 post-
operatively among patients with II type diabetes 
(Fig. 4). The preoperative logMAR BCVA changed 
from 1. 39 ± 0.66 to 1.26 ± 0.56 postoperative-
ly among patients with TRD. The preoperative 
logMAR BCVA changed from 1.90 ± 0.07 to 
1.65 ± 0.12 postoperatively among patients with 
VH (Fig. 5).
IOP was elevated after PPV in nine eyes (eight 
eyes with silicone oil tamponade and one eye with 
gas tamponade) and was managed with topical 
antiglaucomatous drugs. Secondary TRD was ob-
served in seven eyes after PPV with silicone oil 
tamponade, and in two cases re-VH appeared in 
patients with silicone oil tamponade.
disCussion
Diabetes is a systemic disease with many system-
ic vascular complications. Glycaemic, blood pressure 
and cholesterol control should be optimised before 
surgery with the internist. Prolonged hyperglycae-
mia in diabetes leads to an increased permeability 
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Figure 5. Comparison of preoperative (pre-OP) and postoperative (post-OP) visual acuity in two groups: with vitreous haemorrhage and 
tractional retinal detachment
Figure 4. Comparison of preoperative (pre-OP) and postoperative (post-OP) visual acuity depending on the type of diabetes (type 1 and 2)
in retinal vessels. These changes may lead to hard 
or soft exudates, macular oedema, and ischaemia, 
which leads to development of neovascularisation 
and the formation of fibrovascular membranes. The 
fibrovascular complex may contract and can result in 
tractional detachment of the retina. The worst com-
plications of diabetes mellitus are TRD and VH. 
These complications are major causes of vision loss 
in patients with PDR. 
Surgical management of these complications of 
proliferative diabetic retinopathy remains one of the 
most complex and challenging vitreo-retinal proce-
dures.
The results of this study showed that PPV leads 
to significant vision improvement at the end of the 
follow-up, both in TRD and VH. Visual improve-
ment was observed in 60% of patients and was 
more pronounced in the VH group. In a study by 
Quamar VA improved in 75% of patients after PPV 
without tamponade [7].
The major complication associated with PPV is 
recurrent VH, which causes visual impairment and 
reoperation. The incidence of recurrent VH in PDR 
was reported in 13–54% of cases [4–7]; in our study 
this incidence was 11%. 
In our study, re-TRD was observed in 41% and 
the reattachment rate was 65%. In the study by 
Quamar the re-TRD was in 50%, which were suc-
cessfully treated by PPV without the use of an ocu-
lar tamponade in 92% [7].
Silicone oil or intraocular gases were almost rou-
tinely used after PPV for severe TRD [8, 9]. In 
our study silicone oil was given as a tamponade in 
66.5%, air tamponade in 29%, and gas tamponade 
in 4.5%. Silicone oil enables stable retina at the time 
of primary vitrectomy. Moreover, using silicone oil 
avoids loss of vision from re-bleeds and maintains 
long-term tamponade in TRD.
In the present study the results of surgical treat-
ment of VH and TRD were analysed together. In 
most of the studies the results are assessed in one 
group only.
Another important postoperative complication 
was elevated IOP in nine cases (20%), Sternfeld et 
al. described similar findings in their retrospective 
studies of vitrectomised eyes [10].
The another postoperative complication is hy-
potony. In our study we did not document a case of 
hypotony. Sternfeld et al. presented 16% of patients 
after PPV with hypotony [10].
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PPV is an effective treatment method of com-
plications of PDR inter alia the TRD and VH sus-
tained over three months. The best benefit from vi-
trectomy was found in type 1 diabetics, who tended 
to be younger and had more severe disease. 
Intraoperative and postoperative complications 
can depend on the severity and duration of the dis-
ease, and control of the blood glucose. 
In conclusion, patients with severe complica-
tions of diabetic retinopathy such as VH or TRD 
can benefit from PPV, although complications may 
affect the final anatomical and functional results.
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